孟鲁司特对过敏性紫癜患儿尿白三烯的影响

The effects of Montelukast on urinary leukotriene of henoch-schonleinpurpura in children

目的测定尿LTE4变化,探讨孟鲁司特治疗过敏性紫癜(HSP)的疗效。方法60例患儿随机分为两组各30例,急性期均予常规治疗,治疗组同时孟鲁司特口服,恢复期继续孟鲁司特治疗2周;对照组恢复期泼尼松治疗2周。ELISA法检测两组治疗前、后尿LTE4水平。结果维持治疗1周,治疗组比对照组LTE4下降更明显(t=28.860,P<0.05),但仍高于正常(F=46.268,P<0.05),需继续治疗。维持治疗2周,两组患儿尿LTE4接近正常(F=2.796,P>0.05),且治疗组比对照组下降更明显(t=4.777,P<0.05)。两组肾脏损害无统计学意义(χ2=0.218,P>0.05)。结论LTE4参与了HSP发病过程,孟鲁司特治疗HSP可提高疗效、改善预后,副作用小。

Objective By measuring the change of urinary LTE4 to discussed Montelukast treatment HSP effect. Methods Sixty patients were randomly divided into a control group of 30 patients treated with conventional therapy, in the recovery use of prednisone treatment in 2 weeks. The treatment group of acute period and recovery period continued to oral Mon- telukast for 2 weeks. Used ELISA for the detection of the two groups before and after treatment urinary LTE4 levels. Re- suits On one week after treatment, the treatment group levels of LTE4 decreased more obviously （t = 28.860,P 〈 0.05）, But still higher than the normal （F = 46.268,P 〈0.05） ,and after two weeks, the treatment group and control group of LTE4 near normal （F = 2.796,P 〉 0.05）, compared to the control group decreased obviously （t = 4.777, P 〈0.05）. Two groups of kidney damage without difference （χ^2=0.218 ,P 〉 0.05）. Conclusion Leukotriene involved in the pathogenesis of HSP, Montelukast for the treatment of HSP can improve the curative effect, to improve the prognosis, small side effect.